AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8641508 — intervention group
Group type: EXPERIMENTAL
Intervention: Embryo transfer on day 3 after OPU
Number of subjects: 643
Study 8641508 — intervention group
Group type: EXPERIMENTAL
Intervention: Embryo transfer on day 5 after OPU
Number of subjects: 643
Study 8641508 — intervention group
Group type: EXPERIMENTAL
Intervention: Embryo transfer on day 3 with exclusively unfragmented embryos
Number of subjects: 643
Study 8641508 — intervention group
Group type: COMPARATOR
Intervention: Embryo transfer on day 3 with embryos containing > 0% and < 20% fragments
Number of subjects: 643
Study 8641508 — intervention group
Group type: EXPERIMENTAL
Intervention: Embryo transfer on day 5 with one or more cavitating embryos
Number of subjects: 643
Study 8641508 — intervention group
Group type: EXPERIMENTAL
Intervention: Embryo transfer on day 5 with morula stages showing signs of starting blastulation
Number of subjects: 643
Study 8641508 — intervention group
Group type: COMPARATOR
Intervention: Embryo transfer on day 5 with embryos not reaching blastulation stage
Number of subjects: 643
Study 8500245 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient self-assessed quality of life questionnaire score
Number of subjects: 804
Study 8500245 — intervention group
Group type: EXPERIMENTAL
Intervention: NYHA functional class
Number of subjects: 804
Study 8500245 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise performance
Number of subjects: 804
Study 8500245 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak heart rate
Number of subjects: 804
Study 8500245 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated venous pressure and cardiomegaly
Number of subjects: 804
Study 3103416 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (2 mg/kg daily of elemental zinc supplement as acetate)
Number of subjects: 32
Study 3103416 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 3103416 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 32
Study 30524185 — intervention group
Group type: EXPERIMENTAL
Intervention: Curettage plus NCH gel (intervention group)
Number of subjects: 60
Study 30524185 — intervention group
Group type: COMPARATOR
Intervention: Curettage alone (control group)
Number of subjects: 60
Study 25344629 — intervention group
Group type: EXPERIMENTAL
Intervention: High cocoa flavanol-containing diet for 3 months
Number of subjects: 0
Study 25344629 — intervention group
Group type: COMPARATOR
Intervention: Low cocoa flavanol-containing diet for 3 months
Number of subjects: 0
Study 22012196 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG) therapy
Number of subjects: 0
Study 22012196 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIG + prednisolone (PSL) therapy
Number of subjects: 0
Study 22012196 — intervention group
Group type: COMPARATOR
Intervention: IVIG therapy
Number of subjects: 0
Study 20458454 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive intervention scheme
Number of subjects: 2398
Study 20458454 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2398
Study 18519295 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive home visits (PHVs) - two visits per year over 2 years
Number of subjects: 196
Study 18519295 — intervention group
Group type: COMPARATOR
Intervention: Control group (no preventive home visits)
Number of subjects: 196
Study 18519295 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive home visits (PHVs)
Number of subjects: 196
Study 15750457 — intervention group
Group type: EXPERIMENTAL
Intervention: TdcP-IPV
Number of subjects: 194
Study 15750457 — intervention group
Group type: COMPARATOR
Intervention: DTacP plus OPV
Number of subjects: 194
Study 12110423 — intervention group
Group type: EXPERIMENTAL
Intervention: Menatetrenone (MK-4) 45 mg daily for 12 months
Number of subjects: 120
Study 12110423 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated group)
Number of subjects: 120
Study 10334139 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP); total dosage, 1,000 microg/d
Number of subjects: 71
Study 10334139 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 7487579 — intervention group
Group type: EXPERIMENTAL
Intervention: Blindfolded
Number of subjects: 34
Study 7487579 — intervention group
Group type: COMPARATOR
Intervention: Blind individuals
Number of subjects: 34
Study 2142486 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin 400 mg per day
Number of subjects: 202
Study 2142486 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin for proven or presumed Gram-positive infection
Number of subjects: 202
Study 2142486 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin for skin and soft tissue infections
Number of subjects: 202
Study 2142486 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin therapy
Number of subjects: 202
Study 2142486 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin serum concentrations
Number of subjects: 202
Study 282051 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin alone
Number of subjects: 3
Study 282051 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin with diuretic or propranolol therapy
Number of subjects: 3
Study 30418549 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster Randomized Trials (CRTs)
Number of subjects: 121
Study 30418549 — intervention group
Group type: COMPARATOR
Intervention: Individually Randomized Trials (IRTs)
Number of subjects: 121
Study 30418549 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological intervention
Number of subjects: 121
Study 30418549 — intervention group
Group type: EXPERIMENTAL
Intervention: Objective outcome
Number of subjects: 121
Study 27027847 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketogenic diet (KD)
Number of subjects: 57
Study 27027847 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (CAU)
Number of subjects: 57
Study 26011208 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Limberg flap (MLF)
Number of subjects: 91
Study 26011208 — intervention group
Group type: COMPARATOR
Intervention: Karydakis flap (KF)
Number of subjects: 91
Study 23490226 — intervention group
Group type: EXPERIMENTAL
Intervention: MF/F 100/10 μg
Number of subjects: 93
Study 23490226 — intervention group
Group type: EXPERIMENTAL
Intervention: MF/F 200/10 μg
Number of subjects: 93
Study 23490226 — intervention group
Group type: EXPERIMENTAL
Intervention: MF/F 400/10 μg
Number of subjects: 93
Study 23490226 — intervention group
Group type: EXPERIMENTAL
Intervention: MF-MDI 200 μg
Number of subjects: 93
Study 23490226 — intervention group
Group type: EXPERIMENTAL
Intervention: MF 200 μg via DPI
Number of subjects: 93
Study 23490226 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study 21607966 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrodiagnostic consultations performed by specialists (neurologists and physiatrists)
Number of subjects: 100
Study 21607966 — intervention group
Group type: COMPARATOR
Intervention: Electrodiagnostic consultations performed by non-specialists
Number of subjects: 100
Study 19628108 — intervention group
Group type: EXPERIMENTAL
Intervention: Chia seed (CS) 25 g mixed in 0.25 L water twice daily for 12 weeks
Number of subjects: 90
Study 19628108 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P) 25 g mixed in 0.25 L water twice daily for 12 weeks
Number of subjects: 90
Study 19628108 — intervention group
Group type: EXPERIMENTAL
Intervention: Chia seed (CS)
Number of subjects: 90
Study 19628108 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 90
Study 16436796 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil
Number of subjects: 24
Study 16436796 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 14687300 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonatal Nurse Practitioner (NNP) model of practice
Number of subjects: 2
Study 14687300 — intervention group
Group type: COMPARATOR
Intervention: Pre-intervention survey
Number of subjects: 2
Study 14687300 — intervention group
Group type: COMPARATOR
Intervention: Post-intervention survey
Number of subjects: 2
Study 11349172 — intervention group
Group type: EXPERIMENTAL
Intervention: Forceps-assisted delivery
Number of subjects: 0
Study 11349172 — intervention group
Group type: COMPARATOR
Intervention: Vacuum-assisted delivery
Number of subjects: 0
Study 9261749 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual psychotherapy and psychopharmacological treatment (study group)
Number of subjects: 100
Study 9261749 — intervention group
Group type: COMPARATOR
Intervention: Routine oncological care (control group)
Number of subjects: 100
Study 7952799 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg furosemide preadsorbed onto 160 mg charcoal
Number of subjects: 8
Study 7952799 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg furosemide preadsorbed onto 200 mg charcoal
Number of subjects: 8
Study 7952799 — intervention group
Group type: COMPARATOR
Intervention: 40 mg furosemide only (reference)
Number of subjects: 8
Study 2977280 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenfluramine treatment
Number of subjects: 9
Study 2977280 — intervention group
Group type: COMPARATOR
Intervention: Baseline autistic group
Number of subjects: 9
Study 30291883 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermia (target 33.0 °C)
Number of subjects: 624
Study 26940688 — intervention group
Group type: EXPERIMENTAL
Intervention: AC->T (doxorubicin and cyclophosphamide followed by docetaxel)
Number of subjects: 3298
Study 26940688 — intervention group
Group type: COMPARATOR
Intervention: TAC (docetaxel, doxorubicin, and cyclophosphamide)
Number of subjects: 3298
Study 26940688 — intervention group
Group type: EXPERIMENTAL
Intervention: AC->T
Number of subjects: 3298
Study 26940688 — intervention group
Group type: COMPARATOR
Intervention: TAC
Number of subjects: 3298
Study 24144196 — intervention group
Group type: EXPERIMENTAL
Intervention: levomilnacipran ER 40 mg/day
Number of subjects: 557
Study 24144196 — intervention group
Group type: EXPERIMENTAL
Intervention: levomilnacipran ER 80 mg/day
Number of subjects: 557
Study 24144196 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 557
Study 22698294 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual reduction
Number of subjects: 50
Study 22698294 — intervention group
Group type: COMPARATOR
Intervention: Intermaxillary fixation (IMF)
Number of subjects: 50
Study 21155174 — intervention group
Group type: EXPERIMENTAL
Intervention: 9-valent pneumococcal polysaccharide-protein conjugate vaccine (PCV9)
Number of subjects: 39836
Study 21155174 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39836
Study 21155174 — intervention group
Group type: EXPERIMENTAL
Intervention: 9-valent pneumococcal polysaccharide-protein conjugate vaccine (PCV9) in HIV-infected children
Number of subjects: 39836
Study 21155174 — intervention group
Group type: COMPARATOR
Intervention: Placebo in HIV-infected children
Number of subjects: 39836
Study 21155174 — intervention group
Group type: EXPERIMENTAL
Intervention: Possible/probable PTB
Number of subjects: 39836
Study 17275026 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimedia educational aids (video- or computer-based)
Number of subjects: 37
Study 17275026 — intervention group
Group type: COMPARATOR
Intervention: Routine procedures
Number of subjects: 37
Study 16643909 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler assessment of blood flow to the follicle and the endometrium; serum concentrations of biochemical markers such as anti‐Müllerian hormone, inhibin B, FSH, LH, and P
Number of subjects: 44
Study 16643909 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 44
Study 16643909 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with recurrent miscarriage
Number of subjects: 44
Study 12829991 — intervention group
Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil (ADV)
Number of subjects: 700
Study 12829991 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 700
Study 10723108 — intervention group
Group type: EXPERIMENTAL
Intervention: Family risk score (FRS)
Number of subjects: 13938
Study 8857016 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated cardiac troponin T levels (> 0.1 ng/mL)
Number of subjects: 855
Study 8857016 — intervention group
Group type: COMPARATOR
Intervention: Lower cardiac troponin T levels (≤ 0.1 ng/mL)
Number of subjects: 855
Study 8857016 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrocardiographic category (ST-segment elevation, ST-segment depression, T-wave inversion)
Number of subjects: 855
Study 8857016 — intervention group
Group type: EXPERIMENTAL
Intervention: CK-MB levels
Number of subjects: 855
Study 8857016 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined model of troponin T levels, electrocardiographic categories, and CK-MB levels
Number of subjects: 855
Study 1536246 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone (two doses of 12 mg, 24 hours apart)
Number of subjects: 77
Study 1536246 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study 1536246 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone
Number of subjects: 77
Study 6401442 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nifedipine 10‐20 mg
Number of subjects: 25
Study 6401442 — intervention group
Group type: COMPARATOR
Intervention: Intravenous clonidine
Number of subjects: 25
Study 6401442 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 31378506 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Intensity Extracorporeal Shockwave Therapy (Li-ESWT)
Number of subjects: 109
Study 31378506 — intervention group
Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 109
Study 31621982 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) treatment
Number of subjects: 384
Study 30439309 — intervention group
Group type: EXPERIMENTAL
Intervention: cf‐DNA in sepsis group (μg/L): 1,438.0 (1,154.0, 1,576.0)
Number of subjects: 105
Study 30439309 — intervention group
Group type: EXPERIMENTAL
Intervention: cf‐DNA in severe sepsis group (μg/L): 2,595.0 (2,162.0, 5,198.0)
Number of subjects: 105
Study 30439309 — intervention group
Group type: EXPERIMENTAL
Intervention: PCT in sepsis group (μg/L): 5.80 (3.28, 8.85)
Number of subjects: 105
Study 30439309 — intervention group
Group type: EXPERIMENTAL
Intervention: PCT in severe sepsis group (μg/L): 17.53 (8.40, 29.61)
Number of subjects: 105
Study 30439309 — intervention group
Group type: EXPERIMENTAL
Intervention: APACHE II score in sepsis group: 13.04±3.03
Number of subjects: 105
Study 30439309 — intervention group
Group type: EXPERIMENTAL
Intervention: APACHE II score in severe sepsis group: 23.29±8.02
Number of subjects: 105
Study 30439309 — intervention group
Group type: EXPERIMENTAL
Intervention: cf‐DNA, PCT, APACHE II combined prediction
Number of subjects: 105
Study 30439309 — intervention group
Group type: EXPERIMENTAL
Intervention: cf‐DNA alone
Number of subjects: 105
Study 30439309 — intervention group
Group type: EXPERIMENTAL
Intervention: PCT alone
Number of subjects: 105
Study 30439309 — intervention group
Group type: EXPERIMENTAL
Intervention: APACHE II alone
Number of subjects: 105
Study 30439309 — intervention group
Group type: EXPERIMENTAL
Intervention: cf‐DNA + PCT
Number of subjects: 105
Study 30439309 — intervention group
Group type: EXPERIMENTAL
Intervention: cf‐DNA + APACHE II
Number of subjects: 105
Study 30439309 — intervention group
Group type: EXPERIMENTAL
Intervention: PCT + APACHE II
Number of subjects: 105
Study 27050801 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone/salmeterol (F/S) in Gly/Gly subjects
Number of subjects: 67
Study 27050801 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone alone (F) in Gly/Gly subjects
Number of subjects: 67
Study 27050801 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone/salmeterol (F/S) in Arg/Arg subjects
Number of subjects: 67
Study 27050801 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone alone (F) in Arg/Arg subjects
Number of subjects: 67
Study 24379169 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP and a 6-month behavioral medicine intervention targeting physical activity (PA) and eating behavior (EB)
Number of subjects: 73
Study 24379169 — intervention group
Group type: COMPARATOR
Intervention: CPAP and advice on the association between weight and OSAS
Number of subjects: 73
Study 21987045 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous needle fasciotomy
Number of subjects: 111
Study 21987045 — intervention group
Group type: COMPARATOR
Intervention: Limited fasciectomy
Number of subjects: 111
Study 19130641 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertrophy protocol (4 sets of 10 repetitions at 75% 1RM)
Number of subjects: 10
Study 19130641 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength protocol (11 sets of 3 repetitions at 90% 1RM)
Number of subjects: 10
Study 19130641 — intervention group
Group type: EXPERIMENTAL
Intervention: Power protocol (8 sets of 6 repetitions of jump squats at 0% 1RM)
Number of subjects: 10
Study 19130641 — intervention group
Group type: EXPERIMENTAL
Intervention: Total work (TW) calculated for all protocols
Number of subjects: 10
Study 18422060 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean corpuscular hemoglobin concentration (MCHC) in patients with hereditary spherocytosis (35.67±1.33 g/dl)
Number of subjects: 94
Study 18422060 — intervention group
Group type: EXPERIMENTAL
Intervention: Red cell distribution width (RDW) in patients with hereditary spherocytosis (20.60±4.5%)
Number of subjects: 94
Study 18422060 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitivity and specificity of MCHC and RDW
Number of subjects: 94
Study 15209811 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone 20 mg oral daily
Number of subjects: 24
Study 15209811 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 24
Study 11576365 — intervention group
Group type: EXPERIMENTAL
Intervention: Index of Coexistent Disease (ICED)
Number of subjects: 1000
Study 11576365 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariable analysis
Number of subjects: 1000
Study 11576365 — intervention group
Group type: EXPERIMENTAL
Intervention: Model R2
Number of subjects: 1000
Study 9704373 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 units of botulinum toxin type A
Number of subjects: 33
Study 9704373 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 units of botulinum toxin type A
Number of subjects: 33
Study 9704373 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 33
Study 9704373 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 units of botulinum toxin type A (second injection)
Number of subjects: 33
Study 7988607 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 127
Study 7988607 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin plus dipyridamole
Number of subjects: 127
Study 7988607 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anticoagulants
Number of subjects: 127
Study 2563797 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual hypnotherapy
Number of subjects: 33
Study 2563797 — intervention group
Group type: EXPERIMENTAL
Intervention: Group hypnotherapy (up to 8 patients)
Number of subjects: 33
Study 2563797 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotherapy (individual and group)
Number of subjects: 33
Study 29996813 — intervention group
Group type: EXPERIMENTAL
Intervention: App-based intervention including unintentional injury prevention
Number of subjects: 2626
Study 29996813 — intervention group
Group type: COMPARATOR
Intervention: Routine education plus app-based parenting education excluding unintentional injury prevention (Control)
Number of subjects: 2626
Study 28427442 — intervention group
Group type: EXPERIMENTAL
Intervention: Verum acupuncture (intervention group)
Number of subjects: 136
Study 28427442 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture (control group)
Number of subjects: 136
Study 26238547 — intervention group
Group type: COMPARATOR
Intervention: Routine Hemoperfusion (HP)
Number of subjects: 14
Study 26238547 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive Hemoperfusion (HP)
Number of subjects: 14
Study 24154906 — intervention group
Group type: EXPERIMENTAL
Intervention: Transhepatic biopsies
Number of subjects: 10
Study 24154906 — intervention group
Group type: COMPARATOR
Intervention: Extrahepatic biopsies
Number of subjects: 10
Study 20070280 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg EPs‐7630
Number of subjects: 400
Study 20070280 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg EPs‐7630
Number of subjects: 400
Study 20070280 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 mg EPs‐7630
Number of subjects: 400
Study 20070280 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study 18327889 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 44
Study 18327889 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 44
Study 16571394 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular electric stimulation (NMES) of the tibialis anterior muscle for 10 minutes, combined with conventional stroke rehabilitation program (5 days a week for 4 weeks)
Number of subjects: 25
Study 16571394 — intervention group
Group type: COMPARATOR
Intervention: Conventional stroke rehabilitation program (5 days a week for 4 weeks)
Number of subjects: 25
Study 12589167 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadruple immunosuppressive therapy (interleukin (IL)‐2 receptor antibody, tacrolimus, mycophenolate mofetil, and prednisone)
Number of subjects: 1
Study 10645510 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance feedback only
Number of subjects: 216
Study 10645510 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient education materials only
Number of subjects: 216
Study 10645510 — intervention group
Group type: EXPERIMENTAL
Intervention: Both feedback and education materials
Number of subjects: 216
Study 10645510 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 216
Study 8986564 — intervention group
Group type: COMPARATOR
Intervention: Indwelling Foley catheter (group 1)
Number of subjects: 119
Study 8986564 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent catheterization (group 2)
Number of subjects: 119
Study 8986564 — intervention group
Group type: COMPARATOR
Intervention: Indwelling Foley catheter
Number of subjects: 119
Study 1280802 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg ibuprofen plus 30 mg codeine
Number of subjects: 26